Influence of Intravenous S-Ketamine on the Pharmacokinetics of Oral Morphine in Healthy Volunteers

Abstract

BACKGROUND: Subanesthetic ketamine may reduce perioperative consumption of opioids. We studied whether intravenous S-ketamine alters the pharmacokinetics of oral morphine in healthy volunteers. METHODS: In this paired, randomized, double-blind, crossover trial, 12 participants under a 2-hour intravenous S-ketamine (0.57 mg/kg/h) or placebo infusion received oral morphine (0.2 mg/kg) at 30 minutes. Plasma concentrations of ketamine, morphine, and their major metabolites were quantified for 24 hours. The primary end point was area under the curve (AUC)0-24of morphine. Other pharmacokinetic variables for morphine and its metabolites were studied as secondary end points. The data were analyzed as between-phase comparisons for each participant using Wilcoxon matched-pairs signed-rank tests (tmax) or paired t-tests on log-transformed variables (other variables). RESULTS: While the AUC0-24was similar between the 2 phases, S-ketamine reduced the AUC0-1.5of oral morphine by 69% (ratio to control, 0.31; 90% confidence interval [CI], 0.15-0.65; P =.0171) and increased its tmaxfrom 0.5 (range, 0.50-1.5) to 1.0 hour (range, 0.50-4.0; P =.010). The AUC0-1.5of morphine-6-glucuronide (M6G) was reduced by 84% (0.16; 90% CI, 0.07-0.37; P =.0025) and maximum plasma concentration (Cmax) by 43% (0.57; 90% CI, 0.40-0.81; P =.0155), while its tmaxwas increased from 1.5 (range, 1.0-2.0) to 4.0 (range, 1.0-8.0; P =.0094) hours by S-ketamine. Similarly, the AUC0-1.5of morphine-3-glucuronide (M3G) was reduced by 85% (0.15; 90% CI, 0.05-0.43; P =.0083), and tmaxincreased from 1.0 (range, 0.5-1.5) to 4.0 hours (range, 1.0-8.0; P =.0063). In addition, the M6G-to-morphine and M3G-to-morphine metabolic AUC ratios were decreased by 47% (0.53; 90% CI, 0.39-0.71; P =.0033) and 52% (0.48; 90% CI, 0.27-0.85; P =.0043) during 0 to 1.5 hours and by 15% (0.85; 90% CI, 0.78-0.92; P =.0057) and 10% (0.90; 90% CI, 0.83-0.98; P =.0468) during 0 to 24 hours, respectively. One participant was excluded from the analyses due to vomiting in the S-ketamine phase. CONCLUSIONS: Intravenous S-ketamine inhibited the metabolism of oral morphine and delayed its absorption, resulting in a net reduction in the exposure to morphine during the first 1.5 hours. Intravenous S-ketamine may delay the absorption and impair the efficacy of orally administered analgesics and other drugs.